Pittsburgh, PA, October 23, 2023 – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference to be held from October 24th – 27th.

Dr. Jonathan Kaufman, CEO of Lipella, said: “2023 continues to be a year of significant milestone achievements for Lipella. Early in the year, we were delighted to report positive topline results from our Phase 2a clinical study of LP-10 for hemorrhagic cystitis. Further details of the results were presented at the international meeting of the American Urologic Association in the second quarter, and full results were published in the International Journal of Urology and Nephrology in the third quarter. We look forward to our upcoming type-C meeting with the FDA regarding LP-10 in the fourth quarter.”

“Additionally, with the recent FDA approval of our Investigational New Drug (IND) application for LP-310 for oral lichen planus. This accomplishment supplements our R&D pipeline with a second phase-2 asset.”

Lipella’s Fall Foliage MicroCap Rodeo presentation will provide details of our recent clinical and operational accomplishments, and how we intend to continue creating value for investors as we move into 2024.

The presentation will begin at 9:30am ET on Wednesday, October 25, 2023. To register to attend and access the presentation, please visit https://www.webcaster4.com/Webcast/Page/2995/49345. Lipella’s management team will be available for one-on-one meetings with approved investors.

To register for a one-on-one meeting with Lipella, please visit MicroCap Rodeo.

About Lipella Pharmaceuticals

Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit www.lipella.com or LinkedIn.

Forward-Looking Statements

This press release includes certain “forward-looking statements.” All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, future operations, financial position, prospects, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as “may,” “will,” “could,” “continue,” “would,” “should,” “potential,” “target,” “goal,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “predicts,” “expects,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other factors. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.

CONTACT

Dr. Jonathan Kaufman, CEO

Lipella Pharmaceuticals

Info@Lipella.com

1-412-894-1853

Jeff Ramson

PCG Advisory

jramson@pcgadvisory.com

SOURCE: Lipella Pharmaceuticals Inc.

Translate »